Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 0.96 |
| ▸ | HTR2B | P41595 | 17/20 | 0.96 |
| ▸ | HTR2A | P28223 | 10/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 2/20 | 0.60 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4138343 | 0.98 | HTR2C (1.00) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4138340 | 0.98 | HTR2C (1.00) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL17985314 | 0.81 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL16585586 | 0.81 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL16590865 | 0.81 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A4KDM1A | |
| SCHEMBL23993626 | 0.81 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A4KDM1A | |
| SCHEMBL19262120 | 0.81 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL16585585 | 0.81 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL13742189 | 0.78 | HTR2C (0.96) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL8123667 | 0.78 | HTR2C (0.62) | HTR2CHTR2BHTR2ASLC6A4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| WO-2005007614-A1 | MONOAMINE OXIDASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 6011 (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 4/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.